Back | Next |
home / stock / mrsn / mrsn message board
Subject | By | Source | When |
---|---|---|---|
expect to go higher here | edwardport | investorshub | 04/08/2020 7:42:14 AM |
* * $MRSN Video Chart 04-07-2020 * * | ClayTrader | investorshub | 04/07/2020 10:45:16 PM |
BUYOUT hmmmm | sanderburwil | investorshub | 04/07/2020 7:23:31 PM |
* * $MRSN Video Chart 01-17-2020 * * | ClayTrader | investorshub | 01/17/2020 9:16:54 PM |
* * $MRSN Video Chart 11-13-19 * * | ClayTrader | investorshub | 11/13/2019 10:45:25 PM |
$MRSN over to $BNGO | BottomBounce | investorshub | 10/23/2019 5:30:23 PM |
* * $MRSN Video Chart 10-10-2019 * * | ClayTrader | investorshub | 10/10/2019 8:04:14 PM |
Abstract out for WCLC..... | jaybe | investorshub | 09/06/2018 1:50:11 AM |
I would add here if I hadn't loaded | jaybe | investorshub | 07/19/2018 2:17:08 PM |
Mersana...after ASCO... | jaybe | investorshub | 06/07/2018 4:33:33 PM |
New patent app published for new linker/scaffold... | jaybe | investorshub | 05/31/2018 3:37:13 PM |
It appears that we have the right CEO. | dorothy52 | investorshub | 05/27/2018 4:21:39 PM |
Good read on CEO Protopapas's path to Mersana... | jaybe | investorshub | 05/26/2018 4:01:54 PM |
Exactly. Looking forward to pre-clinical on next | jaybe | investorshub | 05/12/2018 8:55:53 PM |
The prize is in the platform/technology. Stay tune | dorothy52 | investorshub | 05/11/2018 10:33:55 PM |
Another Her2 ADC competitor down for the count.... | jaybe | investorshub | 04/25/2018 2:01:57 AM |
Mersana ex-CMO lands at Relay Therapeutics.... | jaybe | investorshub | 04/05/2018 2:40:02 PM |
XMT-1522 Late-breaker at AACR in April... | jaybe | investorshub | 03/15/2018 3:39:53 AM |
Potential competitor MEDI4276 flames out... | jaybe | investorshub | 03/09/2018 3:29:38 AM |
Thanks for the updates jaybe | dorothy52 | investorshub | 03/07/2018 10:40:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...